ProQR Therapeutics NV Company Profile (NASDAQ:PRQR)

About ProQR Therapeutics NV (NASDAQ:PRQR)

ProQR Therapeutics NV logoProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA). It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010 and QR-110. It is focusing on developing QRX- 911, QRX- 021, QRX- 313, QRX- 704, QRX- 812, QRX- 411, QRX- 504, QRX- 604 and QRX- 203. QR-010 is an RNA-based oligonucleotide. QR-110, is an oligonucleotide.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PRQR
  • CUSIP: N/A
  • Web: www.proqr-tx.com
Capitalization:
  • Market Cap: $119.33 million
  • Outstanding Shares: 23,865,000
Average Prices:
  • 50 Day Moving Avg: $4.97
  • 200 Day Moving Avg: $4.58
  • 52 Week Range: $3.65 - $8.70
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.49
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.46 million
  • Price / Sales: 81.73
  • Book Value: $2.09 per share
  • Price / Book: 2.39
Profitability:
  • EBIDTA: ($43,170,000.00)
  • Return on Equity: -48.21%
  • Return on Assets: -41.85%
Debt:
  • Debt-to-Equity Ratio: 0.06%
  • Current Ratio: 8.90%
  • Quick Ratio: 8.90%
Misc:
  • Average Volume: 60,203 shs.
  • Beta: 0.87
  • Short Ratio: 1.44
 

Frequently Asked Questions for ProQR Therapeutics NV (NASDAQ:PRQR)

What is ProQR Therapeutics NV's stock symbol?

ProQR Therapeutics NV trades on the NASDAQ under the ticker symbol "PRQR."

How were ProQR Therapeutics NV's earnings last quarter?

ProQR Therapeutics NV (NASDAQ:PRQR) posted its earnings results on Wednesday, May, 17th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.02. View ProQR Therapeutics NV's Earnings History.

Where is ProQR Therapeutics NV's stock going? Where will ProQR Therapeutics NV's stock price be in 2017?

5 equities research analysts have issued twelve-month price objectives for ProQR Therapeutics NV's shares. Their forecasts range from $4.50 to $40.00. On average, they expect ProQR Therapeutics NV's share price to reach $16.38 in the next year. View Analyst Ratings for ProQR Therapeutics NV.

Are investors shorting ProQR Therapeutics NV?

ProQR Therapeutics NV saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 132,463 shares, an increase of 2.2% from the April 13th total of 129,576 shares. Based on an average daily volume of 12,916 shares, the short-interest ratio is presently 10.3 days.

Who are some of ProQR Therapeutics NV's key competitors?

Who owns ProQR Therapeutics NV stock?

ProQR Therapeutics NV's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (11.07%), Redmile Group LLC (6.65%), Janus Capital Management LLC (1.64%), Sphera Funds Management LTD. (1.41%), FMR LLC (1.02%) and Principal Financial Group Inc. (0.33%). View Institutional Ownership Trends for ProQR Therapeutics NV.

Who sold ProQR Therapeutics NV stock? Who is selling ProQR Therapeutics NV stock?

ProQR Therapeutics NV's stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Janus Capital Management LLC and Morgan Stanley. View Insider Buying and Selling for ProQR Therapeutics NV.

Who bought ProQR Therapeutics NV stock? Who is buying ProQR Therapeutics NV stock?

ProQR Therapeutics NV's stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD. and Hikari Power Ltd. View Insider Buying and Selling for ProQR Therapeutics NV.

How do I buy ProQR Therapeutics NV stock?

Shares of ProQR Therapeutics NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ProQR Therapeutics NV stock cost?

One share of ProQR Therapeutics NV stock can currently be purchased for approximately $5.00.

Analyst Ratings

Consensus Ratings for ProQR Therapeutics NV (NASDAQ:PRQR) (?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $16.38 (227.50% upside)

Analysts' Ratings History for ProQR Therapeutics NV (NASDAQ:PRQR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/1/2017HC WainwrightReiterated RatingBuy$40.00N/AView Rating Details
10/31/2016Chardan CapitalReiterated RatingHold$4.50N/AView Rating Details
10/14/2016Leerink SwannReiterated RatingOutperform$14.00N/AView Rating Details
9/28/2016Janney Montgomery ScottInitiated CoverageNeutral$7.00N/AView Rating Details
9/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for ProQR Therapeutics NV (NASDAQ:PRQR)
Earnings by Quarter for ProQR Therapeutics NV (NASDAQ:PRQR)
Earnings History by Quarter for ProQR Therapeutics NV (NASDAQ:PRQR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/17/20173/31/2017($0.50)($0.48)$0.32 millionViewN/AView Earnings Details
5/18/2016Q1($0.41)($0.50)$0.22 millionViewN/AView Earnings Details
2/17/2016Q4($0.35)($0.29)ViewN/AView Earnings Details
11/23/2015Q3($0.36)($0.29)ViewN/AView Earnings Details
8/19/2015($0.32)($0.41)ViewN/AView Earnings Details
5/21/2015($0.29)$0.01ViewN/AView Earnings Details
2/26/2015($0.27)($0.30)ViewN/AView Earnings Details
11/24/2014($1.00)($0.53)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ProQR Therapeutics NV (NASDAQ:PRQR)
2017 EPS Consensus Estimate: ($2.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.49)($0.49)($0.49)
Q2 20171($0.51)($0.51)($0.51)
Q3 20171($0.53)($0.53)($0.53)
Q4 20171($0.57)($0.57)($0.57)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ProQR Therapeutics NV (NASDAQ:PRQR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ProQR Therapeutics NV (NASDAQ:PRQR)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for ProQR Therapeutics NV (NASDAQ:PRQR)
Latest Headlines for ProQR Therapeutics NV (NASDAQ:PRQR)
Source:
DateHeadline
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Short Interest Up 2.2% in April
www.americanbankingnews.com - May 22 at 4:14 PM
americanbankingnews.com logoBrokers Issue Forecasts for ProQR Therapeutics NV's Q3 2017 Earnings (PRQR)
www.americanbankingnews.com - May 19 at 7:28 AM
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - May 18 at 10:44 AM
finance.yahoo.com logoProQR Announces Results for the First Quarter of 2017
finance.yahoo.com - May 17 at 7:15 PM
finance.yahoo.com logoProQR remembers co-founder Henri Termeer after his unexpected passing
finance.yahoo.com - May 15 at 9:48 AM
finance.yahoo.com logoProQR Announces R&D Day in New York on June 15
finance.yahoo.com - May 9 at 11:00 AM
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Earning Somewhat Negative News Coverage, Study Shows
www.americanbankingnews.com - May 4 at 10:37 AM
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 3 at 10:03 AM
finance.yahoo.com logoProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
finance.yahoo.com - May 1 at 11:11 AM
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Earning Somewhat Critical News Coverage, Study Shows
www.americanbankingnews.com - April 28 at 3:54 PM
finance.yahoo.com logoProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients
finance.yahoo.com - April 27 at 10:36 AM
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Receives Media Sentiment Rating of -0.16
www.americanbankingnews.com - April 22 at 7:32 AM
finance.yahoo.com logoProQR to Present at the Deutsche Bank Health Care Conference
finance.yahoo.com - April 20 at 8:48 AM
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 19 at 7:29 AM
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Receives Media Sentiment Score of 0.31
www.americanbankingnews.com - April 13 at 7:46 PM
finance.yahoo.com logoProQR Announces Annual Meeting of Shareholders
finance.yahoo.com - April 10 at 9:38 AM
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 7 at 9:05 PM
us.rd.yahoo.com logo7:05 am ProQR Therapeutics announces the grant of two key patents protecting QR-010 in the US and EU, these patents provide the Co exclusive rights for QR-010 for the treatment of cystic fibrosis until at least July 2033
us.rd.yahoo.com - April 3 at 11:47 PM
finance.yahoo.com logoProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
finance.yahoo.com - March 27 at 9:38 AM
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Downgraded by Zacks Investment Research to “Hold”
www.americanbankingnews.com - March 13 at 2:48 PM
finance.yahoo.com logoProQR to Present at Two Upcoming Investor Conferences in March
finance.yahoo.com - March 1 at 7:36 PM
us.rd.yahoo.com logoProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update
us.rd.yahoo.com - February 28 at 3:49 PM
finance.yahoo.com logoOn a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day
finance.yahoo.com - February 27 at 9:44 AM
finance.yahoo.com logoCan The Uptrend Continue for ProQR Therapeutics (PRQR)?
finance.yahoo.com - December 29 at 8:58 AM
finance.yahoo.com logoBlog Coverage ProQR Cystic Fibrosis Drug Meets Primary End Point
finance.yahoo.com - October 28 at 10:41 AM
nasdaq.com logoMid-Morning Market Update: Markets Open Higher; Twitter Beats Q3 Expectations
www.nasdaq.com - October 27 at 11:52 AM
finance.yahoo.com logoProQR Therapeutics (PRQR) Worth a Look: Stock Up 9.8%
finance.yahoo.com - October 27 at 11:52 AM
thestreet.com logoProQR Cystic Fibrosis Drug Passes First, Early Efficacy Test
www.thestreet.com - October 27 at 11:52 AM
finance.yahoo.com logoProQR Jumps on Positive Phase 1 Results
finance.yahoo.com - October 27 at 11:52 AM
finance.yahoo.com logoProQR Therapeutics N.V. (PRQR) is Overbought: Is A Drop Coming?
finance.yahoo.com - September 27 at 6:45 PM
finance.yahoo.com logoProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis
finance.yahoo.com - July 19 at 7:00 AM
finance.yahoo.com logoCoverage initiated on ProQR Therapeutics by Chardan Capital Markets
finance.yahoo.com - June 20 at 5:50 AM
finance.yahoo.com logo7:04 am ProQR Therapeutics confirms that its investigational drug QR-110 has received orphan drug designation from both the FDA and the EMA for the treatment of Leber's congenital amaurosis Type 10
finance.yahoo.com - June 1 at 7:04 AM
finance.yahoo.com logoProQR to Present at the Leerink Partners Global Healthcare Conference
finance.yahoo.com - February 3 at 7:00 AM
finance.yahoo.com logoWhy ProQR Therapeutics (PRQR) Stock Might be a Great Pick
finance.yahoo.com - December 22 at 8:33 AM
finance.yahoo.com logoProQR Therapeutics (PRQR) Rises: Stock Up 6.1% in Session
finance.yahoo.com - December 9 at 8:45 AM
finance.yahoo.com logoPROQR THERAPEUTICS N.V. Financials
finance.yahoo.com - December 8 at 1:09 PM
finance.yahoo.com logoProQR Announces R&D Day and Provides Update on Innovation Portfolio
finance.yahoo.com - November 30 at 7:00 AM
finance.yahoo.com logoProQR Therapeutics (PRQR) Falls: Stock Goes Down 24.8%
finance.yahoo.com - November 24 at 8:50 AM

Social

Chart

ProQR Therapeutics NV (PRQR) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff